Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Israeli Chemist Discovers Link Between Type 2 Diabetes and Parkinson’s Disease
http://www.thetower.org/1195oc-israeli-chemist-discovers-link-between-type-2-diabetes-and-parkinsons-disease/
Israeli chemist Yifat Miller and her PhD student Yoav Atsmon-Raz have found a critical link between Type 2 diabetes (T2D) and Parkinson’s disease (PD). Miller’s research at Ben-Gurion University (BGU) of the Negev in Beersheva revealed, for the first time, the atomic structure of a brain protein fragment called non-amyloid beta component (NAC), known to trigger PD when it clumps together. The same clumping action by an endocrine hormone called amylin harms insulin-producing beta cells in the pancreas, leading to T2D. Amylin is also found in the brain, and previous studies show that its clumping there, with the aid of the peptide amyloid beta, is related to Alzheimer’s disease (AD) and the death of neurons. Miller suspected that this mechanism explains why people with T2D face twice the normal risk of developing AD later in life. With these findings, she strongly suspected she was closing in on a groundbreaking key to understanding of the mechanism that underlies T2D and neurodegenerative diseases.
Miller’s second goal was to shed more light on Parkinson’s and other neurodegenerative diseases, as well as the reason why people with type 2 diabetes have a higher risk for developing PD and not only AD. Miller’s hypothesis was that amylin can also interact with NAC or alpha-synuclein. This study spanned nearly three years of research using sophisticated computer simulations. The findings were then confirmed through experiments.
Miller set up her lab in BGU in 2011 after three years of post-doctoral research on AD at the National Institutes of Health in Maryland. With her staff of four graduate students and one post-doctoral researcher, she focuses on the link between type 2 diabetes and neurodegenerative diseases. Miller’s lab may continue investigating this further. (via Israel21c)
SUNSTAR Wednesday, 10/15/14 09:59:10 AM
Re: None
Post # of 193739
Bavituximab’s broad spectrum targets are cancers, enveloped viruses, like Ebola, and other diseases. It’s bavi’s universal target, PS, that is densely associated with these diseases, that will drive PPHM as the FDA approvals occur.
This broad spectrum universality of bavituximab will drive PPHM market cap growth exponentially from here going forward.
Bavi will be one the the first immunotherapy agents approved by FDA, IMO, allowing Peregrine to move from a small cap pharmaceutical, to directly competing with big pharmas for market share.
Broad spectrum means market leverage.
IMO
sunstar
Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection
Peer-Reviewed Data Show Peregrine Pharmaceuticals' PS-Targeting Antibody Bavituximab Exhibits Specific and Strong Binding to Ebola Virions and Ebola Virus-Infected Cells In Vitro; Data Supplement Published Scientific Literature Suggesting the Important Role of PS in Ebola Infection in Viral Entry and Immune Suppression During Infection
TUSTIN, CA -- (Marketwired) -- 10/15/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the publication of a peer-reviewed manuscript related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus (EBOV)-infected cells in vitro. These results will appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions."
"The recent outbreaks of Ebola infections highlight the need for novel clinical treatments and new combinations that are effective in treating the disease. We have a number of active collaborations exploring the potential of PS-targeting antibodies in infectious diseases and the results just published, along with a growing body of scientific literature, support potential applications of our PS-targeting platform in virus infections including Ebola," said Jeff T. Hutchins, Ph.D. vice president, preclinical research at Peregrine Pharmaceuticals. "Evolution has favored pathogenesis that exposes PS and these published results, along with other recently to be published data, have shown that PS is present during Ebola virus infection1-3 and is important in the infection process. While our primary focus remains on advancing bavituximab in oncology, including our SUNRISE Phase III lung cancer trial, we believe these data warrant further collaborative investigation in Ebola and other infectious diseases including combinations with vaccines and active therapies that have shown promise."
The manuscript details the results from a study demonstrating that exposed PS allows for the specific binding of bavituximab to purified Ebola virions and EBOV-infected cells in vitro. Previous published studies have shown that surface exposure of PS antigen is a consequence of viral infection. Published results in other lethal viral hemorrhagic fever animal model (Pichinde virus infection model in guinea pigs)5 suggest that PS-targeting antibodies can bind to exposed PS and limit viral infection by initiating the removal of virions from the bloodstream through the induction of antibody-dependent cellular cytotoxicity (ADCC) as well as eliminate virus-infected cells.
"Our goal with this work was to continue exploring the potential of bavituximab in the antiviral arena and in this case, specifically in biodefense applications," said Cyril Empig, Ph.D., associate research director at Peregrine Pharmaceuticals. "With the increased focus on Ebola, there is an opportunity to take advantage of the specificity of bavituximab for Ebola virus and develop therapeutics or treatment regimens that could neutralize the virus. In addition, recently reported genomic sequence variations in EBOV suggest that drugs targeting specific viral non-variant proteins or protein sequences are at risk of failure as a result of virus escape mutations.4 We believe that there are advantages to utilizing bavituximab in a treatment regimen against Ebola virus given its great specificity for Ebola virions and Ebola-infected cells, its potential to circumvent the problem of virus escape mutations given that it is targeting a host molecule rather than a virus protein or protein sequence, and the possible role of PS in immunosuppression during Ebola infection.1 Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."
A link to the provisional manuscript can be found on the front page of the company's website at www.peregrineinc.com
About Bavituximab: A Targeted Immunotherapy
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. To date, bavituximab has been administered to over 600 patients worldwide and appears to be safe and well tolerated. Bavituximab's target, PS, is a highly immunosuppressive lipid molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of virus-infected cells, virus particles themselves, as well as tumor cells and cells that line tumor blood vessels, creating a specific target for anti-viral and anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal potentially enabling the immune system to better recognize and fight tumors and infectious pathogens. Data published in peer-reviewed journals shows that PS-targeting antibodies such as bavituximab mediate important immune-stimulatory changes.5,6 As part of the SUNRISE trial, bavituximab is being evaluated in a Phase III, global, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and efficacy of bavituximab plus docetaxel as second-line treatment in patients with non-small cell lung cancer. Bavituximab is also currently being evaluated in several solid tumor indications, including breast cancer, liver cancer, rectal cancer and melanoma. For additional information about the SUNRISE trial please visit www.SunriseTrial.com or www.ClinicalTrials.gov using Identifier NCT01999673.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that future preclinical or clinical studies with bavituximab do not establish that PS is an adequate target to clear Ebola virus and infected cells, the risk that future preclinical studies or clinical studies with bavituximab do not circumvent the problem of virus escape mutations or show that PS plays a role in immunosuppression during Ebola infection. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
1 S. Bhattacharyya et al. 2013. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of tam receptors. Cell Host Microbe. 14, 136-147, doi:10.1016/j.chom.2013.07.005.
2 S. Jemielity et al. 2013. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 9:e1003232.
3 K. Morizono et al. 2014. Role of Phosphatidylserine Receptors in Enveloped Virus Infection. J. Virol. 88: 4275-4290.
4 S.K. Gire et al., 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, doi: 10.1126/science.1259657.
5 Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature Medicine 2008 Dec;14(12):1357-62.
6 Yi Yin, Xianming Huang, Kristi D. Lynn, and Philip E. Thorpe. Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation. Cancer Immunology Research; 1(4); 256-68.
Oh my f'in lord...back to bavi curing ebola...SICK-O's.
ISIS terrorists caught entering U.S. through southern border in last 36 hours
According to Judicial Watch, it has been confirmed by Homeland Security sources that four Islamic terrorists have been apprehended in the last 36 hours by federal authorities and the Texas Department of Public Safety in McAllen and Pharr. California Congressman Duncan Hunter, a former Marine Corp Major and member of the House Armed Services Committee, disclosed on national television that at least ten Islamic State of Iraq and Greater Syria (ISIS) fighters have been caught crossing the Mexican border in Texas.
A Texas National Guard soldier scans the Mexican side of the U.S.–Mexico border in Havana, Texas.
A Texas National Guard soldier scans the Mexican side of the U.S.–Mexico border in Havana, Texas.
Photo by John Moore/Getty Images
Hunter believes, “If you really want to protect Americans from ISIS, you secure the southern border.” He went on to point out that, "ISIS doesn’t have a navy, they don’t have an air force, they don’t have nuclear weapons. The only way that ISIS is going to harm Americans is by coming in through the southern border – which they already have.”
Rep. Jason Chaffetz, a Republican from Utah, said four alleged terror suspects were captured on Sept. 10 in Texas. In an interview with BuzzFeedNews on Wednesday, Chaffetz said the men flew from a Middle Eastern country to Mexico City, where they paid a smuggler to take them to and across the border. From there, the men ended up in a safe house for immigrants. They were en route to New York City, Chaffetz said, when they were captured.
Although Chaffetz would not reveal his source of the information, he said he confirmed it with government officials. “I had an informant tell me about it and then I questioned the Secretary of Homeland Security,” he said. “I have no doubt about its authenticity.”
CBS reported on Wednesday that the Department of Homeland Security released a statement that claims alleging Islamic State militants have been apprehended at the Mexican border are “categorically false.” The DHS insists they have no credible intelligence that suggests terrorist organizations are actively plotting to cross the southwest border. Homeland Security Secretary Jeh Johnson says that Islamic State militants are not entering the U.S. through the southern border. Johnson was responding to a claim made by Rep. Duncan Hunter, R-Calif., that at least 10 Islamic State operatives were detained trying to come in from Mexico.
Congressman Hunter, however, isn't buying that explanation. His spokesman told BuzzFeed News Wednesday that they have evidence from reliable sources about “foreign nationals” being captured along the border. Kasper said those foreign nationals may not technically be ISIS fighters, but do have suspected terror group affiliations. Kasper did not identify his sources but said that Hunter’s office remains convinced that the lawmaker was correct.
Our worst fears may already be realized because despite the recent surge of immigrants from Central America and other parts of the world at the southern border, the Obama administration has been unwilling to deploy the National Guard or other military assets to back up the Border Patrol. With the Border Patrol overwhelmed by a massive influx, illegal immigrants have been walking across the southern border into Texas from at least 75 different countries, and not just from Central America. Many of those apprehended in the Rio Grande area and elsewhere are released into the country after being initially detained by Border Patrol agents.
Is it plausible that ISIS is already in America after crossing the U.S.-Mexican border
Any books out there by investors who got rich on "hope"...? I didn't think so.
Well you have to call it like it is!!!
The Hope producers.
. . . . . SO JAZZY ..... :)
WHAT A JOKE, THEY'VE BEEN TRYING TO KNOCK IT DOWN ALL AM. PHLX MARKET MAKER KEEPS FLASHING ON THE BID.
COMPLETELY MANIPULATED, NO DOUBT.
ONLY PEOPLE TRADING THIS POS ARE HEDGIES AND SHORTERS
Seven straight weeks DOWN...down-trending moving averages showing their worth as they act as resistance. This sch!tty stock is a cancer in its own right.
PPHM is a wretched and rotten piece of garbage. Funny how the POS board goes hand in hand with that.
Personally, I believe the PR on Monday was that MUSHY PR, which did nothing for the Share Price. If last year was any indicator, then the PPS will continue to decrease to the ASM like it did last year.
October 2, 2013: $1.48
October 17, 2013 (ASM): $1.40
October 24, 2013: $.137
So far this year:
October 2, 2014: $1.32
October 16, 2014: My guess $1.18-$1.25...
Cloaked Protector working overtime tonight. Has an answer for everything. He must be so smart.
Yup. They have no skin in the game. They may have spent 10-25k on stock themselves. Options are meaningless. If that had any decent financial advice they would have been advised to load up on options and sell this pos. Look At the CEO of puma bio. He sold cougar bio and will do the same with puma bio. That's a CEO with a plan. That's how you make real money. Not nickel and diming on salaries. Idiots.
There riding the big salaries as long as they can. With a PIII in progress it can go another 2-3 if results are bad. If they are good then they have options. win/win for themselfs
BOD and management are completely incompetent. This should have been partnered or sold by now.
I think we get a few mushy PR's before the ASM and we go higher into meeting. but will get nothing out of ASM and we drift downward to RS after
If we wait any longer it will be $0.00
Who is CP anyway?
It's one big circle jerk over there with CP in the middle.
Management is perfect, you just wait what the pps will be.
I AGREE. STRAIGHT TO THE SLAUGHTERHOUSE. HE DOES KNOW EVERYTHING. DOESN'T HE? LOL. WHAT AMAZES ME IS HOW THESE IDIOTS ACTUALLY BELIEVE HIM AND THEY THINK HE IS HELPFUL. UNBELIEVABLE.
HE IS A PAID SCHILL ..........
AMAZING HOW HE THINKS HE HAS THE ANSWER TO EVERYTHING ....THE PIED PIPER OF PPHM LEADING PEOPLE TO THE SLAUGHTER .IMO
THE BULLSHIT HE SPEWS IS RELENTLESS !!!!!!!!!!!!
Who is paying Cloaked Protector to keep posting on the pos board?
I hope so. This is pathetic. What a bunch of amateurs running this pos
Do you think there is at least one spike left? I just want to get out now with a small loss instead of a large one.
DOWN SHE GOES.
WHEW! What a STENCH over there on the POS board...stock and posters...whew, that's some toxic sch!t! P.S. - DOO-DAH, DOO-DAH.
Hello all y'all!! FYI, BTW, FWIW NOVARTIS HAS DOUBLED DOWN ON CANCER BY SELLING THEIR NON CANCER DIVISIONS OFF FOR MEGA BILLIONS$$ like the vaccine/Hygienebiz for over $9 BILLION to Glaxo .... THINK CARTs and T CELL treatements for many types of cancer ... Through Sloan Kettering they do know of Bavituximab and down the road may be a "player" for either collaboration or buyout of PPHM ... JUZ SAYIN' ... Wink wink ..... Ciao & Shalom!!
PPHM could have a link with Ebola,and it's not a good one. If by chance the talking heads are lying to us and this turns into a pandemic,then the health care systems in the US and Europe will become overwhelmed. This could effectively hinder or kill our CT. I presently do not subscribe to this viewpoint,but think it is something to consider.
THANKS, JAKE. I KNOW WHO PETER K. IS AND I WAS ALSO TOLD HE WAS NOTBOB17, SO THAT WAS WHAT I WAS TRYING TO CLEAR UP.
RCJ
RCJ........
I THINK HE IS WRONG ON GOLFHO BEING PETER K ..
PETER K IS NOTBOB17 ..........
AND OUT OF RESPECT FOR PETER K I WON'T REVEAL WHO HE IS BUT A HINT WOULD BE A VERY FAMOUS GOLF ANNOUNCER AND TEACHER AND HE HAS BEEN IN PPHM AS LONG OR LONGER THAN ME..........
You know it's Admin not Mods that delete most post don't you? 95% of me deletions are admin not the mods. I can assure you Golfho's post (aka Peter K right) was an admin delete. PG
GOOD LORD ...IS THIS MAN A TOTAL IDIOT OR WHAT ???
DUBAI, United Arab Emirates (AP) — Vice President Joe Biden on Sunday called the crown prince of the United Arab Emirates to clarify that he did not mean to imply in his remarks last week that the Gulf ally was supporting al-Qaida fighters in Syria, the White House said.
Biden: I didn't mean to imply UAE aided al-Qaida Associated Press
UAE says Biden apologizes for any implication it supported militants Reuters
Biden apologizes to Turkey president in phone call Associated Press
Turkey's Erdogan attacks Biden claims it funded extremists AFP
Syria blasts coalition against Islamic State Associated Press
Biden spoke with Mohamed bin Zayed Al Nahyan, the crown prince of Abu Dhabi and a key Emirati leader, the White House said.
It was the second time in two days that Biden had to call a key partner in President Barack Obama's coalition to walk back comments he made on Thursday, when he said that U.S. allies — including Turkey, Saudi Arabia and the UAE — had funded and armed extremist groups linked to al-Qaida
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
UTSW Collaborators Found Phosphatidylserine (PS)-Targeting Antibody in Combination With an Anti-PD-1 or an Anti-CTLA-4 Immune Checkpoint Inhibitor Promotes a Robust, and Localized Anti-Tumor Response in Models of Melanoma and Breast Cancer; Statistically Significant Tumor Growth Suppression With Combination of PS-Targeting Antibody and Anti-PD-1 Versus Antibody Alone in Breast and Melanoma Models; Lead PS-Targeting Antibody Bavituximab in a Phase III Trial in Second-Line Non-Small Cell Lung Cancer and a First Immunotherapy Combination Trial With Ipilimumab (Yervoy(R)) in Advanced Melanoma
TUSTIN, CA -- (Marketwired) -- 10/06/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody. Data show that PS-targeting agents in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4, promote a robust and localized anti-tumor response in models of melanoma and breast cancer and decrease levels of myeloid derived suppressor cells (MDSC) in the tumor microenvironment. Newly generated data show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma. These data will be presented this morning at the Cancer Research Institutes' "Cancer Immunotherapy: Out of the Gate" conference being held at the Grand Hyatt Hotel in New York, New York.
"We are pleased to be presenting this exciting data to this immuno-oncology focused audience," said Jeff T. Hutchins, Ph.D. vice president, preclinical research at Peregrine Pharmaceuticals "These data are impressive and consistent in their findings across several tumor types and further build on the rationale for additional collaborative studies such as the ongoing investigator-sponsored Phase Ib trial of bavituximab in combination with ipilimumab (Yervoy®) in advanced melanoma."
The poster titled: "Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of immune checkpoint inhibitors by affecting myeloid-derived suppressor cell (MDSC) and lymphocyte populations in the tumor microenvironment" will be presented by Rolf Brekken, Ph.D., Effie Marie Cain Research Scholar in Angiogenesis Research and an Associate Professor, in the Departments of Surgery and Pharmacology at the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center in Dallas, Texas. Data from these studies show that the PS-targeting antibody ch1N11, the preclinical equivalent to bavituximab, significantly enhances tumor growth inhibition of anti-CTLA-4 or anti-PD-1 in the B16 and K1735 melanoma models and the efficacy of anti-PD-1 in the EMT-6 breast tumor model. New data show that the combination of ch1N11 and an anti-PD-1 antibody produce a statistically significant difference (p=0.018) in tumor growth suppression over anti-PD-1 alone in the B16 melanoma model. In addition, PS blockade with ch1N11 combined with either anti-CTLA-4 or anti-PD-1 resulted in greater T cell infiltration into B16 and K1735 tumors than tumors treated with either antibody alone. Consistent with these results, ch1N11 combined with anti-PD-1 showed an enhanced percentage of T cells producing the cytokines IL-2 and IFNg, factors associated with immune activation, when compared with T cells from tumors being treated with anti-PD-1 alone. In summary, the targeting and blocking of PS with ch1N11 significantly improved the anti-tumor efficacy of immune checkpoint blockade in robust models of melanoma and breast cancer in immunocompetent animals.
The link to the poster can be found from the front page of the company's website at: www.peregrineinc.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from potential human clinical studies involving combinations of PS-targeting agents with immune checkpoint inhibitors such as anti-PD-1 or anti-CTLA-4 may not correlate with the data from the preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Yervoy is a registered trademark of Bristol-Meyers Squibb.
Contact:
Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
JAKE. WE ALL KNOW IHUBS OWNERS HISTORY
IT JUST GOES TO SHOW HOW FUKKED UP POS BOARD REALLY IS..
ONE OF THE MOST RESPECTED POSTERS(GOLFHO) FOR A LONG LONG TIME POSTS AND EVERYONE SAYS WHAT A GREAT POST IT IS AND MODS DELETE IT ...THAT IS ONE GARBAGE BOARD OVER THERE ....LEMMY , I DON'T KNOW WHY YOU EVEN WASTE YOUR TIME WITH THEM.........